-
MSD announces an increase in sales forecast for the entire year of 2023
On October 26, MSD announced an increase in its sales forecast for the entire year of 2023. MSD released its financial results for the third quarter of 2023 on its official website: global total sale ... -
MSD PD-1 inhibitor approved by the US FDA
On January 12th local time, Merck announced that the US Food and Drug Administration (FDA) has approved the use of Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (C ... -
Li Zhengqing, Senior Vice President Global and President of Research and Development in China at Merck: Nine valent HPV vaccine adds a second dose vaccination program for women aged 9-14, and Merck "increases efforts" to eliminate cervical cancer
On January 9, 2024, MSD announced that its second dose vaccination program for the nine valent human papillomavirus (HPV) vaccine targeting women aged 9-14 has been approved by the National Medical P ... -
Approval of new indications for Mercado Pembrolizumab
On February 4th, Merck&Company announced that its PD-1 inhibitor pembrolizumab has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment in combinatio ...